Radiopharmaceutical Dosimetry for Cancer Therapy
Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice
The Journal of Nuclear Medicine, Supplement 62:3 (December 2021)
Guest Editors: Richard L. Wahl, MD, and John Sunderland, PhD
Can the tailoring of drug dosage improve the effectiveness of radiopharmaceutical therapy (RPT) for cancer patients? The Journal of Nuclear Medicine has issued a new supplement addressing both the rapid progress and the challenges in applying patient-specific radiation dosimetry to guide RPT.
Although patient-specific dosimetry has been used in the past for RPT with good results, it may not be necessary or effective for all radiopharmaceuticals. However, with new nuclear medicine therapies approved or under review by the U.S. Food and Drug Administration and achieving pass-through status with the Centers for Medicare and Medicaid Services, further discussion is warranted. When does dosimetry improve outcomes? How can it be accommodated in current practice? What commercial tools are available? How about reimbursement?
These articles provide a useful starting point and review for sites considering implementing dosimetry in their clinical practice or research operations.
80 pages
Member Price: $45.00
NonMember Price: $63.00
Purchase Now
